These findings support the mechanism whereby the two biomarkers, enriched in lymphatic metastatic LSCC, are consistently associated with the Wnt/β-catenin or PI3K signaling pathways, thus leading to tumor-promoting effects. Here, PIK3CA is linked to neoplasm.